Browsing Tag
Cancer immunotherapy
23 posts
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.
OSR Holdings (NASDAQ: OSRH) explores royalty-driven licensing for Vaximm’s cancer therapy
Vaximm may license its oral cancer therapy VXM01 in a deal worth up to $815M. Find out how OSR Holdings plans to turn this into a royalty-driven biotech play.
Vaximm AG advances VXM01 strategy with BCM Europe term sheet offering US$20m upfront and US$815m upside
Learn how Vaximm AG’s new term sheet with BCM Europe sets the stage for a US$20M upfront license deal and up to US$815M in milestones.
Why OSR Holdings (NASDAQ: OSRH) chose its scientific founder to lead Vaximm’s next immunotherapy chapter
OSR Holdings appoints scientific founder Dr. Andreas Niethammer as CEO of Vaximm AG to lead next-gen cancer immunotherapy strategy. Read more.
Ernexa Therapeutics (NASDAQ: ERNA) surges 68% after Cellipont deal to advance ovarian cancer cell therapy ERNA‑101
Ernexa Therapeutics stock jumps 68% after partnering with Cellipont to manufacture its ovarian cancer cell therapy ERNA-101. Learn what’s driving investor interest.
HanchorBio and Henlius sign $202m licensing deal for HCB101 to expand immuno-oncology access across Asia and MENA
HanchorBio Inc. (7827.TWO), a clinical-stage immunotherapy innovator, has entered a major licensing agreement with Shanghai Henlius Biotech Inc.…
Percheron Therapeutics (ASX: PER) licenses HMBD-002 cancer drug from Hummingbird in oncology pivot
Percheron Therapeutics acquires global rights to phase II-ready cancer drug HMBD-002 from Hummingbird Bioscience. Learn what this means for investors.
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a…
CStone Pharmaceuticals advances CS2009 clinical trial, targeting multi-billion-dollar immunotherapy market
CStone Pharmaceuticals has officially commenced the Phase I clinical trial for CS2009, a cutting-edge PD-1/VEGF/CTLA-4 trispecific antibody, marking…
Akeso advances cancer immunotherapy as Ivonescimab reaches Phase III milestone in lung cancer treatment
Akeso, Inc. (9926.HK) has completed patient enrollment for its pivotal Phase III trial (HARMONi-6), marking a significant step…